Search results for "INFECTIONS"

showing 10 items of 2671 documents

Auswirkungen eines neuen Wassersystems auf nosokomiale Kolonisierung oder Infektion mit Pseudomonas aeruginosa

2016

Aim: We aimed to study the impact of new water systems, which were less contaminated with P. aeruginosa, on the incidence of healthcare-associated P. aeruginosa cases (colonizations or infections) in care units that moved to a different building between 2005 and 2014. Methods: Generalized Estimated Equations were used to compare the incidence of P. aeruginosa healthcare-associated cases according to the building. Results: Twenty-nine units moved during the study period and 2,759 cases occurred in these units. No difference was observed when the new building was compared with older buildings overall. Conclusion: Our results did not support our hypothesis of a positive association between wat…

0301 basic medicinelcsh:Public aspects of medicineTrinkwassersystem030106 microbiologylcsh:Rlcsh:QR1-502lcsh:Medicinelcsh:RA1-1270030501 epidemiology610 Medical sciences; Medicineinfection controllcsh:MicrobiologyArticlenosokomiale Infektionen3. Good healthInfektionskontrolle03 medical and health sciences[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseaseswater systemshealthcare-associated infectionsddc: 610[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesNosocomial infectionsPseudomonas aeruginosa0305 other medical scienceGMS Hygiene and Infection Control
researchProduct

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct

Caenorhabditis elegans as an in vivo model to assess fucoidan bioactivity preventing Helicobacter pylori infection

2020

Currently, Helicobacter pylori is the unique biological carcinogenic agent. The search for antimicrobial alternatives to antibiotics against this pathogen has been categorized as a priority due to the drastic failure associated with current applied antibiotic therapy. The present study assessed the bioactive antimicrobial capability of fucoidan (“Generally Recognized as Safe” approval – European Commission December 2017) from different species of Phaeophyceae algae (Fucus vesiculosus, Undaria pinnatifida, Macrocystis pyrifera) against H. pylori. All the studied fucoidans showed bacteriostatic and bactericidal effects at the studied concentrations [5–100] μg ml−1 and exposure times [0–7 days…

0301 basic medicinemedicine.drug_classAntibioticsPhaeophytaMicrobiologyHelicobacter Infections03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalAnti-Infective AgentsIn vivoPolysaccharidesGenerally recognized as safemedicineAnimalsCaenorhabditis elegansPathogenbiologyHelicobacter pyloriFucoidanGeneral MedicineHelicobacter pyloribiology.organism_classificationAntimicrobial3. Good healthDisease Models Animal030104 developmental biologychemistry030220 oncology & carcinogenesisFood Science
researchProduct

Minor environmental concentrations of antibiotics can modify bacterial virulence in co-infection with a non-targeted parasite.

2018

Leakage of medical residues into the environment can significantly impact natural communities. For example, antibiotic contamination from agriculture and aquaculture can directly influence targeted pathogens, but also other non-targeted taxa of commensals and parasites that regularly co-occur and co-infect the same host. Consequently, antibiotics could significantly alter interspecific interactions and epidemiology of the co-infecting parasite community. We studied how minor environmental concentrations of antibiotic affects the co-infection of two parasites, the bacterium Flavobacterium columnare and the fluke Diplostomum pseudospathaceum , in their fish host. We found that antibiotic in …

0301 basic medicinemedicine.drug_classAntibioticsVirulenceOxytetracyclineAquacultureTrematode InfectionsinfektiotFlavobacteriumantibioticsMicrobiologybakteerit03 medical and health sciencesFish DiseasesAntibiotic resistanceco-infectionAquacultureFlavobacteriaceae InfectionsloisetDrug Resistance BacterialmedicineWater Pollution ChemicalParasite hostingAnimalsbacteriabiologyVirulencebusiness.industryCoinfectionimumadotta1183antibiootitvirulenssiCommensalismbiology.organism_classificationAgricultural and Biological Sciences (miscellaneous)Anti-Bacterial Agents030104 developmental biology13. Climate actionympäristövaikutuksetOncorhynchus mykissFlavobacterium columnareparasiteta1181TrematodaGeneral Agricultural and Biological SciencesbusinessPathogen BiologyBacteriaBiology letters
researchProduct

The unusual structure of Ruminococcin C1 antimicrobial peptide confers clinical properties.

2020

The emergence of superbugs developing resistance to antibiotics and the resurgence of microbial infections have led scientists to start an antimicrobial arms race. In this context, we have previously identified an active RiPP, the Ruminococcin C1, naturally produced by Ruminococcus gnavus E1, a symbiont of the healthy human intestinal microbiota. This RiPP, subclassified as a sactipeptide, requires the host digestive system to become active against pathogenic Clostridia and multidrug-resistant strains. Here, we report its unique compact structure on the basis of four intramolecular thioether bridges introduced post-translationally by a specific radical-SAM sactisynthase. This structure con…

0301 basic medicinemedicine.drug_class[CHIM.THER] Chemical Sciences/Medicinal ChemistryAntibioticsgut microbiomeContext (language use)Peptide[CHIM.THER]Chemical Sciences/Medicinal Chemistry010402 general chemistry01 natural sciencesMicrobiologyClostridia03 medical and health sciencesRuminococcus gnavusantibioticmedicineRiPPHumansIntestinal Mucosa[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitologychemistry.chemical_classificationRadical SAM enzymeClostridialesMultidisciplinarybiologyRiPPs Ruminococcin C sactipeptide gut microbiome antibiotic[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyBacterial InfectionsBiological Sciencesbiology.organism_classificationAntimicrobialIntestinal epithelium[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology0104 chemical sciences3. Good healthsactipeptideAnti-Bacterial AgentsRuminococcus gnavusRiPPs030104 developmental biology[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologychemistryRuminococcin CPeptidesBacteriaProceedings of the National Academy of Sciences of the United States of America
researchProduct

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

2021

Background & Aims A number of double, triple, and quadruple therapies have been proposed as first-line empiric treatments for Helicobacter pylori infection. However, knowledge of their worldwide and regional comparative efficacy is lacking. We examined the comparative effectiveness of all empirically used first-line regimens tested against standard triple treatment using a network meta-analysis of published randomized controlled trials. Methods Data extracted from eligible randomized controlled trials were entered into a Bayesian network meta-analysis to investigate the comparative efficacy of H pylori infection empiric first-line regimens and to explore their effectiveness rank order. The …

0301 basic medicinemedicine.medical_specialtyComparative Effectiveness ResearchTime FactorsEfficacyVonoprazanSettore MED/12 - GASTROENTEROLOGIANetwork Meta-Analysislaw.inventionHelicobacter Infections03 medical and health sciences0302 clinical medicineRandomized controlled trialDrug TherapyLevofloxacinlawInternal medicinemedicineHumansFirst-Line RegimensRandomized Controlled Trials as TopicHepatologybiologyHelicobacter pyloribusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyBayes TheoremProton Pump InhibitorsOdds ratioHelicobacter pyloribiology.organism_classificationConfidence intervalAnti-Bacterial AgentsTreatmentRegimen030104 developmental biologyTreatment OutcomeMeta-analysisCombination030211 gastroenterology & hepatologyDrug Therapy Combinationbusinessmedicine.drug
researchProduct

Managing cancer patients during the COVID-19 pandemic:an ESMO multidisciplinary expert consensus

2020

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed …

0301 basic medicinemedicine.medical_specialtyConsensusCoronavirus disease 2019 (COVID-19)Settore MED/18 - CHIRURGIA GENERALEPneumonia ViraleducationDiseaseMedical OncologyReal-Time Polymerase Chain ReactionSpecial Article03 medical and health sciencesBetacoronavirus0302 clinical medicineMultidisciplinary approachNeoplasmsPandemicGranulocyte Colony-Stimulating FactorMedicineHumansDisease management (health)PandemicsSocieties Medicalbusiness.industrySARS-CoV-2Expert consensusCOVID-19Disease ManagementcovidHematologyTelemedicineEurope030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicineCancer managementSevere acute respiratory syndrome coronavirusbusinessCoronavirus InfectionsT-Lymphocytes Cytotoxic
researchProduct

Detection of temporal clusters of health care-associated infections or colonizations with Pseudomonas aeruginosa.

2016

International audience; We investigated temporal clusters of Pseudomonas aeruginosa cases between 2005 and 2014 in 1 French university hospital, overall and by ward, using the Kulldorff method. Clusters of positive water samples were also investigated at the whole hospital level. Our results suggest that water outlets are not closely involved in the occurrence of clusters of P aeruginosa cases.

0301 basic medicinemedicine.medical_specialtyEpidemiology030106 microbiology030501 epidemiologymedicine.disease_causeHealth care associatedMicrobiologyHospitals University03 medical and health sciences[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicinemedicineCluster AnalysisHumansPseudomonas InfectionsCross InfectionPseudomonas aeruginosabusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthWaterHospital levelUniversity hospital3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyCarrier StatePseudomonas aeruginosaFranceWater Microbiology0305 other medical sciencebusiness
researchProduct

Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotes…

2020

Abstract Background: Some countries have implemented stand-alone human papillomavirus (HPV) testing while others consider cotesting for cervical cancer screening. We compared both strategies within a population-based study. Methods: The MARZY cohort study was conducted in Germany. Randomly selected women from population registries aged ≥30 years (n = 5,275) were invited to screening with Pap smear, liquid-based cytology (LBC, ThinPrep), and HPV testing (Hybrid Capture2, HC2). Screen-positive participants [ASC-US+ or high-risk HC2 (hrHC2)] and a random 5% sample of screen-negatives were referred to colposcopy. Post hoc HPV genotyping was conducted by GP5+/6+ PCR-EIA with reverse line blottin…

0301 basic medicinemedicine.medical_specialtyEpidemiologyPopulationUterine Cervical NeoplasmsAlphapapillomavirusCervical cancer screeningSensitivity and SpecificityCohort Studies03 medical and health sciences0302 clinical medicinePregnancyCytologymedicineHumanseducationPapillomaviridaeEarly Detection of CancerVaginal SmearsColposcopyeducation.field_of_studymedicine.diagnostic_testbusiness.industryObstetricsPapillomavirus InfectionsConfidence interval030104 developmental biologyOncologyColposcopy030220 oncology & carcinogenesisVerification biasLiquid-based cytologyFemalebusinessPapanicolaou TestCohort studyCancer Epidemiology, Biomarkers & Prevention
researchProduct

An "aubergine" in the heart: huge native mitral valve endocarditis caused by Streptococcus agalactiae.

2017

0301 basic medicinemedicine.medical_specialtyFever030106 microbiologyMEDLINE030204 cardiovascular system & hematologymedicine.disease_causeStreptococcus agalactiae03 medical and health sciencesMitral valve endocarditis0302 clinical medicineStreptococcal InfectionsInternal MedicinemedicineHumansIntensive care medicineEndocarditisbusiness.industryMiddle AgedDyspneaStreptococcus agalactiaeItalyEchocardiographyEmergency MedicineChordae TendineaeMitral ValveFemalebusinessEmergency Service HospitalInternal and emergency medicine
researchProduct